Accepted Preprint (first posted online 17 October 2016)

    Nesfatin-1: functions and physiology of a novel regulatory peptide

    1. Carla Schulz
    1. R Dore, Department of Internal Medicine I, University of Lübeck, Luebeck, 23538, Germany
    2. L Levata, Department of Internal Medicine I, University of Luebeck, Luebeck, Germany
    3. H Lehnert, Department of Internal Medicine I, University of Luebeck, Luebeck, Germany
    4. C Schulz, Department of Internal Medicine I, University of Luebeck, Luebeck, Germany
    1. Correspondence: Carla Schulz, Email: carla.schulz{at}uksh.de

    Abstract

    Nesfatin-1 was identified in 2006 as a potent anorexigenic peptide involved in the regulation of homeostatic feeding. It is processed from the precursor-peptide NEFA/nucleobindin 2 (NUCB2) which is expressed both in the central nervous system as well as in the periphery, from where it can access the brain via non-saturable transmembrane diffusion. In hypothalamus and brainstem, nesfatin-1 recruits the oxytocin-, the melancortin- and other systems to relay its anorexigenic properties. NUCB2/nesfatin-1 peptide expression in reward-related areas suggests that nesfatin-1 might also be involved in hedonic feeding. Besides its initially discovered anorexigenic properties, over the last years other important functions of nesfatin-1 have been discovered, many of them related to energy homeostasis, e.g. energy expenditure and glucose homeostasis. Nesfatin-1 is not only affecting these physiological processes, but alterations of the metabolic state (e.g. fat mass, glycemic state) also have an impact on the synthesis of NUCB2 and release of NUCB2 and/or nesfatin-1. Furthermore, nesfatin-1 exerts pleiotropic actions at the level of cardiovascular and digestive systems, as well as plays a role in stress response, behavior and sleep. Despite the recent advances in nesfatin-1 research, a putative receptor has not been identified and furthermore potentially distinct functions of nesfatin-1 and its precursor NUCB2 have not been dissected yet. To tackle these open questions will be major objectives of future research to broaden our knowledge on NUCB2/nesfatin-1.

    • Received 3 August 2016
    • Received in final form 14 September 2016
    • Accepted 17 October 2016
    • Accepted Preprint first posted online on 17 October 2016

    This Article

    1. J Endocrinol JOE-16-0361
    1. Abstract
    2. Supplementary Data
    3. All Versions of this Article:
      1. JOE-16-0361v1
      2. 232/1/R45 most recent

    Article Metrics